WHO prequalifies Serum Institute’s CERVAVAC vaccine
Quick dive
- The World Health Organization prequalified Serum Institute’s CERVAVAC quadrivalent HPV vaccine.
- The vaccine received recognition for quality, safety and efficacy.
- WHO prequalification can support eligibility for United Nations procurement.
- CERVAVAC targets human papillomavirus through a quadrivalent vaccine formulation.
- exam_relevance: The development is relevant to vaccine regulation, cervical-cancer prevention, global health procurement and India’s pharmaceutical capacity.
Full explanation
This explanation is available with full current-affairs access.
Log in to continue